Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) Seqirus, suspension for injection in pre-filled syringe. Presentation: Each 0.5 ml of cell-based quadrivalent influenza vaccine (QIVc) contains 15 micrograms of each of four purified virus strains propagated in Madin Darby Canine Kidney (MDCK) cells that comply with the World Health Organization (WHO) Quadrivalent Influenza Vaccine (aQIV) recommendations (Northern Hemisphere) for the current season. Indications: Prophylaxis of influenza in adults and children from 2 years of age. Dosage and Administration: Adults and children aged 2 years and over should receive a single 0.5 ml dose, children less than 9 years of age who have not been previously vaccinated against influenza, should receive a second dose at least 4 weeks apart. For intramuscular injection only. The preferred site for injection is the deltoid muscle of the upper arm. Young children with insufficient deltoid muscle should be vaccinated in the anterolateral aspect of the thigh. Contraindications: Hypersensitivity to the active substance, to any of the excipients (sodium chloride, potassium chloride, magnesium chloride hexahydrate, disodium phosphate dihydrate, potassium dihydrogen phosphate), or to possible trace residues (beta-propionolactone, cetriyltrimethylammonium bromide, and polysorbate 80). Warnings and Precautions: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event (e.g. anaphylaxis). Local and systemic reactions compared to adults aged 18 years and over. Elderly: and fever in adults and elderly were uncommon. The following skin reactions (erythema multiforme, urticaria, pruritus or non-specific syndrome, convulsions, neuritis, neuralgia, paraesthesia), generalised rash, vasculitis that may be associated with transient renal involvement. If QIVc is to be used at the same time as another vaccine, it should be administered at separate injection sites and preferably on different limbs. Adverse reactions may be intensified by any co-administration. Data assessed by the MHRA supports concomitant administration of QIVc with COVID-19 mRNA Vaccine BNT162b2 (Pfizer/BioNTech) and COVID-19 Vaccine AstraZeneca. The data show that the antibody responses are unaffected and that the reactogenicity profile is acceptable. Pregnancy and Lactation: Inactivated influenza vaccines, such as QIVc, can be given in any stage of pregnancy. Larger safety datasets are available on vaccine use during the second or third trimester, compared with the first trimester. Data from worldwide use of influenza vaccines do not indicate any adverse foetal or maternal outcomes attributable to the vaccine. Effects on Ability to Drive and Use Machines: QIVc has no or negligible influence on the ability to drive and use machines. Side Effects: The most common reactions (≥1/10) are injection-site pain, and fatigue. Commonly reported adverse reactions (≥1/100 to <1/10) include nausea, vomiting, diarrhoea, arthralgia, chills/shivering and fever (≥38°C). Vomiting in the elderly, and fever in adults and elderly were uncommon. The following have been reported post-marketing: extensive swelling of injected limb, allergic reactions (including anaphylactic shock), paraesthesia, and generalised skin reactions (including pruritus, urticaria, or non-specific rash). Paediatric subjects generally reported higher rates of local and systemic reactions compared to adults aged 18 years and over. One rare condition that may be associated with transient renal involvement. Overdose: Overdose is unlikely to have any untoward effect. Legal Category: POM. Package Quantities: Packs of 1 or 10 pre-filled syringes. Marketing Authorisation Number: PLGB 47991/0006. Basic NHS Cost: £12.50 per 0.5ml pre-filled syringe. £125.00 per 10-pack. Marketing Authorisation Holder: Seqirus UK Ltd., Point, 29 Market Street, Maidenhead SL6 8AA, United Kingdom. For full prescribing information and details of other side effects, see the Summary of Product Characteristics: www.medicines.org.uk/emc/product/12882. GBR-CQIV-22-0004. Date of preparation: August 2022.

Adjuvanted quadrivalent influenza vaccine (surface antigen, inactivated) Seqirus, suspension for injection in pre-filled syringe. Presentation: Each 0.5 ml dose of adjuvanted quadrivalent influenza vaccine (aQIV) contains 15 micrograms of each of the four strains that comply with the World Health Organization (WHO) Quadrivalent Influenza Vaccine (aQIV) recommendations (Northern Hemisphere) for the current season. Indications: Prophylaxis of influenza in elderly (65 years of age and older). Dosage and Administration: A single 0.5 ml dose by intramuscular injection (preferred site is the deltoid muscle of the upper arm). Contraindications: Hypersensitivity to the active substances, components of the adjuvant, excipients (sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate), or to possible trace residues (ovalbumin, kanamycin, neomycin sulphate, formaldehyde, cetyltrimethylammonium bromide, hydrocortisone). A severe allergic reaction (e.g. anaphylaxis) to previous influenza vaccination. Warnings and Precautions: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event (e.g. anaphylaxis). Local and systemic reactions compared to adults aged 18 years and over. Elderly:另有症状，如昏迷、抽搐、癫痫发作，可能继续进行。确保程序是适当的。心血管症状如短暂视力障碍，感觉异常和肌阵挛性抽搐等。神经系统症状，如短暂的视觉障碍，针刺感和刺痛感，以及短暂的运动障碍，如对肌肉的上臂和大腿。对可能出现的全身性免疫反应，Injectable influenza vaccines, such as QIVc, can be administered with caution to individuals with thrombocytopenia or bleeding disorder since bleeding may occur following intramuscular administration. Syncope (fainting) can occur following or before any vaccination. The following are the symptoms of a severe allergic reaction (e.g. anaphylaxis). Vomiting in the elderly, and fever in adults and elderly were uncommon. The following skin reactions (erythema multiforme, urticaria, pruritus or non-specific syndrome, convulsions, neuritis, neuralgia, paraesthesia), generalised rash, vasculitis that may be associated with transient renal involvement. If QIVc is to be used at the same time as another vaccine, it should be administered at separate injection sites and preferably on different limbs. Adverse reactions may be intensified by any co-administration. Data assessed by the MHRA supports concomitant administration of Flud (trivalent formulation) with COVID-19 mRNA Vaccine BNT162b2 (Pfizer/BioNTech) and COVID-19 Vaccine AstraZeneca. The data show that the antibody responses are unaffected and that the reactogenicity profile is acceptable. Pregnancy and Lactation: This vaccine is for use in elderly adults 65 years and older. It is not to be used in women who are, or may be, pregnant or breast-feeding. Effects on Ability to Drive and Use Machines: No or negligible influence on the ability to drive and use machines. Side Effects: The most common reactions (≥1/10) are headache, injection-site pain, and fatigue. Commonly reported adverse reactions (≥1/100 to <1/10) include nausea, vomiting, diarrhoea, arthralgia, chills/shivering and fever (≥38°C). Vomiting in the elderly, and fever in adults and elderly were uncommon. The following have been reported post-marketing: extensive swelling of injected limb, allergic reactions (including anaphylactic shock), paraesthesia, and generalised skin reactions (including pruritus, urticaria, or non-specific rash). Paediatric subjects generally reported higher rates of local and systemic reactions compared to adults aged 18 years and over. Overdosage: Overdose is unlikely to have any untoward effect. Legal Category: POM. Package Quantities: Packs of 1 or 10 pre-filled syringes. Marketing Authorisation Number: 47991/0007. Basic NHS Cost: £12.50 per 0.5ml pre-filled syringe. £125.00 per 10-pack. Marketing Authorisation Holder: Seqirus UK Ltd., Point, 29 Market Street, Maidenhead SL6 8AA, United Kingdom. For full prescribing information and details of other side effects, please see the Summary of Product Characteristics: www.medicines.org.uk/emc/product/12882. GBR-AQIV-22-0003. Date of preparation: August 2022.